PTPN12 knockouts in a Drosophila screening model were observed to be phenotypically resistant to TKIs used to treat CML [36], whereas other cellular phosphatases like PTPN1 (PTP1B), PTPN6 (SHP-1), and PTPN11 (SHP-2) are substrates of Abl1 kinase. This evidence concerns the gene PTPN6 and chronic myelogenous leukemia, BCR-ABL1 positive.